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Introduction
During ischemic events, coronary blood flow is restricted causing cardiomyocytes to
enter a hypoxic state. This in turns leads to uncoupling of the mitochondrial electron
transport chain. When bloodflow and oxygen delivery is restored during reperfusion,
reactive oxygen species (ROS) are generated which leads to the loss of mitochondrial
membrane potential and opening of the mitochondrial permeability transition pore
(MPTP) which potentiate mitochondrial fission in MI/R. Mitochondrial fission is
associated with mitochondrial fragmentation and decreased ATP production, leading to
cardiac contractile dysfunction and increased infarct size in MI/R (Figure 1) (1,2,3)

infarct size in isolated perfused rat hearts. Previously it was shown that TAT-P110
exerted a modest (i.e. one-third) reduction in infarct size compared to untreated
controls, however cardiac function was not reported in the study nor was their a
comparison of TAT-P110 to native peptide in isolated perfused rat hearts subjected to
MI(30min)/R(90min)(2). Myristic acid conjugated peptides enter into cells by simple
diffusion whereas tat-conjugated peptides enter into cells via an endocytosis
mechanism involving interaction with positively-charged amino acids (i.e.,
RKKRRQRRR) with the negatively charged plasma cell membrane (4,5). Native
peptides enter through facilitated diffusion (Figure 3).
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Figure 3. Cell entry mechanisms for Native, Tat, and Myr-P110. The a.a. sequence of TAT, GG spacer, and P110 is depicted above.

Hypothesis

Figure 1. Acute myocardial ischemia results in a decrease in pH due to the build up of lactic acid from anaerobic conditions. The
acidic conditions during ischemia prevent the opening of the mitochondrial permeability transition pore (MPTP) and cardiomyocyte
hypercontracture at this time. Reperfusion results in washout of lactic acid, resulting in the rapid restoration of physiological pH,
which releases the inhibitory effect on the MPTP opening, Ca2+ overload, and cardiomyocyte hypercontracture. The restoration of
the mitochondrial membrane potential drives Ca2+ into the mitochondria, which can also induce MPTP opening and cardiac
contractile dysfunction. Neutrophils accumulate in the infarcted myocardial tissue in response to the release of chemoattractants,
and generate ROS. Adapted from Hausenloy and Yellon 2013 (1).

Figure 5. Time course of dP/dtmax for Sham, I/R and I/R + Tat-P110, Myr-P110 and Native P110 hearts. Myr-P110 significantly
improved post-reperfused dP/dtmax compared to untreated I/R, Tat-P110, and Native hearts. Sham hearts maintained cardiac function
throughout the experimental protocol (87±9% of initial LVDP and 89±8% of initial dP/dt max ). (*p<0.05 compared to untreated I/R
hearts; # p<0.05 compared to Native hearts; ^ p<0.05 compared to Tat-P110 hearts).

We hypothesize that Myr-P110 (1 μM) will significantly improve postreperfused cardiac
function and reduce infarct size compared to untreated control I/R hearts or native
P110 (1 μM) given 10min. prior to ischemia and for 20min. at the beginning of
reperfusion. We also predict that TAT-P110 (1 μM), will significantly improve
postreperfused cardiac function and reduce infarct size compared to untreated control
Therefore, inhibiting mitochondrial fission which results from the vital act of reperfusion,
I/R hearts or native P110 (1 μM) but to a lesser extent than Myr-P110.
may be a strategy to salvage damaged cardiomyocytes and protect them from MI/R
injury. P110 (DLLPRGT) is a cell permeable mitochondrial fission peptide inhibitor that
acts by selectively inhibiting the interaction between human fission protein (Fis1), which
is located on the outer mitochondrial membrane and dynamin related protein 1 (Drp1), Isolated Rat Heart Preparation
a GTPase (Figure 2).
Male Sprague Dawley rats (275-325 g, Charles River, Springfield,

Methods

Figure 2. Mechanism of mitochondrial fission in MI/R and P110’s inhibition of interaction between Drp1 and Fis1. Mitochondrial
membrane potential (MMP) is increased and reactive oxygen species (ROS) is decreased with P110. Adapted from Qi 2013. (3)

It is well known that adding myristic acid or tat carrier peptide to native peptides will
facilitate cell membrane permeability required for targeting intracellular substrates. The
addition of a glycine-glycine spacer between the tat and cargo portion of the peptide is
reported to facilitate better delivery of the cargo sequence (i.e., DLLPRGT) (3,4). We
have previously shown that myristic acid conjugated caveolin-1 and PKC βII and ζ
peptide inhibitors significantly attenuated leukocyte chemotactic receptor stimulated
superoxide release compared to their native counterparts (5). However, it is not known
if differences exist in the effectiveness of myristic acid versus tat conjugated peptides
compared to their native counterparts or untreated controls in MI/R. In the current study
we compared the effects of TAT-conjugated P110 (MW= 2427g/mol), Myristoylated
P110 (MW=981 g/mol), and Native P110 (MW=771 g/mol) on cardiac function and

MA) were anesthetized with a pentobarbital sodium (60 mg/kg)
and sodium heparin (1,000 U) injection intraperitoneally. Each
heart was rapidly excised, immersed in a 160 mL water-jacketed
reservoir and subjected to retrograde perfusion via the aorta with
a modified Krebs-Henseleit buffer. The perfusate was maintained
at 37oC, kept at 80 mmHg constant pressure, aerated with 95%
O2-5% CO2 and equilibrated at a pH of 7.35-7.45. A flow meter
(T106, Transonic Systems, Inc., Ithaca, NY) placed in the inflow
line monitored coronary flow. Left ventricular end-systolic
pressure (LVESP), left ventricular end-diastolic pressure
(LVEDP),
(LVEDP) heart rate and peak rates of rise and fall in the first derivative (dP/dtmax and
dP/dtmin, respectively) of left ventricular developed pressure (LVDP) were monitored
using a pressure transducer (SPR-524, Millar Instruments, Inc., Houston, TX) positioned
in the left ventricular cavity and recorded using a Powerlab Station acquisition system
(ADInstruments, Grand Junction, CO). LVDP was calculated by subtracting LVEDP
from LVESP. At the end of reperfusion, five heart slices (2 mm/slice) were subjected to
1% triphenyltetrazolium chloride (TTC) staining to detect dead (unstained) and viable
(red stained) area. Infarct size was expressed as the percentage of dead tissue to the
total tissue weight. Experimental protocol is shown in Fig. 4 (6).
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Figure 4. Once a stable baseline was established, some I/R hearts were given P110 (1 µM) for 10 min. at a rate of 1 mL/min prior to
ischemia. Thereafter, ischemia was induced by stopping buffer flow. Buffer flow was restored while infusing 5 mL of autologous
plasma and 15 mL of Krebs’ buffer ± P110 (1 µM) at a rate of 1 mL/min for 20 min. Left ventricular sections were stained in TTC to
detect infarct size.

Statistical Analysis
All data in the text and figures are presented as means ± SEM. Cardiac function and
TTC staining data were analyzed by ANOVA using post hoc analysis with the StudentNewman-Keuls test. Probability values of <0.05 were considered statistically significant.

Figure 6. Representative TTC stained heart sections displayed above from sham, control I/R and I/R + P110 treated hearts were
assessed after cardiac function experiments to determine infarct size. Weight ratios of infarcted to at risk left ventricular tissue in I/R as
determined by TTC staining. Myr-P110 1μM significantly reduced infarct size compared to untreated I/R hearts (*P<0.05). Sham hearts
had minimal cell death (<0.05%) at the end of the experimental protocol .

Conclusions
These data suggest excessive mitochondrial fission contributes to MI/R injury. Myr-P110
(1μM) significantly improved post-reperfused dP/dtmax and reduced infarct size as
compared to untreated, control, Tat, and Native P110 hearts. Tat-P110 transiently
improved postreperfused cardiac function but did not reduce infarct size compared to
Native P110. The data suggest that Myr-P110 is the more effective formulation and may
be an attractive strategy to attenuate MI/R injury and salvage heart tissue in MI patients.
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